- Home
- MRK vs TGTX Comparison
MRK vs TGTX Comparison
Compare MRK & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- TGTX
- Stock Information
- Founded
- MRK 2000
- TGTX 1993
- Country
- MRK United States
- TGTX United States
- Employees
- MRK N/A
- TGTX N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- TGTX Health Care
- Exchange
- MRK Nasdaq
- TGTX Nasdaq
- Market Cap
- MRK 198.5B
- TGTX 4.2B
- IPO Year
- MRK N/A
- TGTX 1995
- Fundamental
- Price
- MRK $81.52
- TGTX $32.22
- Analyst Decision
- MRK Buy
- TGTX Strong Buy
- Analyst Count
- MRK 15
- TGTX 5
- Target Price
- MRK $107.21
- TGTX $45.00
- AVG Volume (30 Days)
- MRK 11.4M
- TGTX 2.1M
- Earning Date
- MRK 10-30-2025
- TGTX 11-03-2025
- Dividend Yield
- MRK 3.99%
- TGTX N/A
- EPS Growth
- MRK 20.41
- TGTX N/A
- EPS
- MRK 6.49
- TGTX 0.36
- Revenue
- MRK $63,616,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- MRK $1.92
- TGTX $82.58
- Revenue Next Year
- MRK $4.97
- TGTX $44.99
- P/E Ratio
- MRK $12.51
- TGTX $88.81
- Revenue Growth
- MRK 1.82
- TGTX 30.96
- 52 Week Low
- MRK $73.31
- TGTX $21.16
- 52 Week High
- MRK $119.38
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- MRK 43.17
- TGTX 57.75
- Support Level
- MRK $80.54
- TGTX $31.29
- Resistance Level
- MRK $82.25
- TGTX $33.33
- Average True Range (ATR)
- MRK 1.38
- TGTX 1.13
- MACD
- MRK -0.50
- TGTX 0.28
- Stochastic Oscillator
- MRK 18.60
- TGTX 75.48
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.